Johnson & Johnson : Real-World Study Confirms Benefit of XARELTO® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients

TITUSVILLE, NJ, December 9, 2022 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that... | December 9, 2022

Related Keywords

United States ,Americans ,American ,Lee Pasqualoni ,Craigi Coleman ,American Heart Association ,Janssen Pharmaceuticals Inc ,Janssen Pharmaceutical Companies ,Janssen Pharmaceutical Companies Of Johnson ,Cardiovascular Metabolism At Janssen Scientific Affairs ,University Of Connecticut ,American Society Of Hematology ,Janssen Scientific Affairs ,Janssenusand Janssen Scientific Affairs ,National Blood Clot Alliance ,Centers For Disease ,None Of The Janssen Pharmaceutical Companies ,School Of Pharmacy ,Exchange Commission ,Companies Of Johnson ,Johnson ,Observational Study ,Cancer Associated Thrombosis ,American Society ,Annual Meeting ,Avery Ince ,Vice President ,Medical Affairs ,Janssen Pharmaceuticals ,Prescribing Information ,Boxed Warnings ,Medication Guidefor ,Pharmaceutical Companies ,Infectious Diseases ,Private Securities Litigation Reform Act ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Blood Clot ,Venous Thromboembolism ,Accessed November ,Disease Control ,Prevention Blood Clots ,Johnson Stock Exchange ,News ,Information ,Press Release ,December ,022 ,The ,Janssen ,Harmaceutical ,Companies ,F ,Oday ,Nnounced ,Observational ,Data ,Rom ,Flight ,Tears ,Linical ,Practice ,Howing Jnj Us4781601046 ,